(Q37232368)

19 August 2017

1 reference

title

Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives (English)

1 reference

19 August 2017

0 references

David L Buckley

4

0 references

Alan Jackson

object named as

Alan Jackson

2

0 references

Gordon C. Jayson

object named as

Gordon C Jayson

6

0 references

author name string

James P B O'Connor

1

1 reference

19 August 2017

Marie-Claude Asselin

3

1 reference

19 August 2017

Geoff J M Parker

5

1 reference

19 August 2017

publication date

1 August 2008

1 reference

Lancet Oncology Commission

19 August 2017

published in

1 reference

19 August 2017

volume

9

1 reference

19 August 2017

issue

8

1 reference

19 August 2017

page(s)

766-776

1 reference

Global cancer statistics, 2002

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Mechanism-based target identification and drug discovery in cancer research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Predicting benefit from anti-angiogenic agents in malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

We should desist using RECIST, at least in GIST.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

On measuring the change in size of pulmonary nodules.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Quantitative contrast-enhanced computed tomography: is there a need for system calibration?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

The progress and promise of molecular imaging probes in oncologic drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

How should we analyse FDG PET studies for monitoring tumour response?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Perfusion CT for the assessment of tumour vascularity: which protocol?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Analysis of dynamic contrast enhanced MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Key factors in the acquisition of contrast kinetic data for oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

A model for capillary exchange

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Are Measurements from Two Commercial Software Packages Interchangeable? Possibly, If Like Is Compared with Like

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Clinical measurement of blood flow in tumours using positron emission tomography: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Strategy for the measurement of regional cerebral blood flow using short-lived tracers and emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

How molecular imaging is speeding up antiangiogenic drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Non-invasive measurement of perfusion: a critical review of arterial spin labelling techniques

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970196-7

7 January 2021

10.1016/S1470-2045(08)70196-7

Identifiers

DOI

1 reference

19 August 2017

1 reference